Marketwired PinPointe FootLaser Receives FDA Clearance for the Treatment of Nail Fungus (Onychomycosis)
The PinPointe(TM) FootLaser(TM) has received clearance from the U.S. Food and Drug Administration for the treatment of nail fungus (onychomycosis), which affects approximately 35 million Americans. Clinical studies show after a single PinPointe FootLaser treatment between 68% and 81% of patients experienced increased clear nail at six and 12 months, and 81 percent of all patients had sustained improvement at 12 months. For more information, visit www. PinPointeFootLaser.com.      
Return to Release | Remove Frame | Source Image available